Treatment of immune thrombocytopenia (ITP) secondary to malignancy: a systematic review

Immune thrombocytopenia (ITP) can be associated with lymphoproliferative diseases (LPD) or solid tumors. A systematic review of published literature was conducted to evaluate response to treatment of ITP secondary to malignancy. Primary outcome was overall response (complete response+response) to fi...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Platelets (Edinburgh) Ročník 33; číslo 1; s. 59 - 65
Hlavní autoři:	Podda, Gian Marco, Fiorelli, Elisa M., Birocchi, Simone, Rambaldi, Benedetta, Di Chio, Maria Chiara, Casazza, Giovanni, Cattaneo, Marco
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Taylor & Francis 02.01.2022 Taylor & Francis Group
Témata:	Humans ITP malignancy Neoplasms - complications Purpura, Thrombocytopenic, Idiopathic - etiology Purpura, Thrombocytopenic, Idiopathic - pathology Purpura, Thrombocytopenic, Idiopathic - therapy secondary ITP ITP malignancy secondary ITP
ISSN:	0953-7104, 1369-1635, 1369-1635
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Immune thrombocytopenia (ITP) can be associated with lymphoproliferative diseases (LPD) or solid tumors. A systematic review of published literature was conducted to evaluate response to treatment of ITP secondary to malignancy. Primary outcome was overall response (complete response+response) to first-line treatments [steroids alone or in combination with intravenous immunoglobulins (IVIg)]. Among secondary outcomes, overall response to second-line treatments [splenectomy, rituximab or thrombopoietin receptor agonists (TPO-RA)] and death were evaluated. Of the retrieved 238 text articles, 108 were analyzable, for a total of 154 patients: 142 in 105 case reports and 12 in 3 observational studies. Thirty-nine patients had solid tumors, 114 LPD, and 1 both. The median follow up was 19 months (IQR, 9-40). The overall response was 50% (62% in solid tumors, 46% in LPD) after steroids and 47% (67% in solid tumors, 36% in LPD) after steroids+IVIg, which are lower than historical responses observed in primary ITP (≈80%). The overall responses to rituximab (used in LPD only), splenectomy and TPO-RA (70%, 73% and 92%, respectively) were similar to those observed in primary ITP. Seven patients (6%) died due to bleeding events. ITP secondary to malignancy appears to be associated with unsatisfactory response to first-line treatments.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ISSN:	0953-7104 1369-1635 1369-1635
DOI:	10.1080/09537104.2020.1822521